Novartis Ag (NVS) Net Cash Flow Growth (3y) (2012 - 2026)
Novartis Ag (NVS) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 37.67% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -129.17% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -10.13% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -98.96% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -51.84% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 8.91% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -68.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.53% |
| Jun 30, 2025 | 57.30% |
| Dec 31, 2024 | -44.46% |
| Sep 30, 2024 | 15.16% |
| Jun 30, 2024 | -46.71% |
| Mar 31, 2024 | -46.52% |
| Dec 31, 2023 | 47.89% |
| Jun 30, 2023 | -41.67% |
| Jun 30, 2022 | -165.46% |
| Dec 31, 2021 | 46.93% |
| Sep 30, 2021 | -11.80% |
| Jun 30, 2021 | -42.98% |
| Dec 31, 2020 | -52.10% |
| Sep 30, 2020 | 67.93% |
| Jun 30, 2020 | 70.96% |
| Dec 31, 2019 | 44.36% |
| Jun 30, 2019 | 44.66% |
| Dec 31, 2018 | 46.24% |
| Sep 30, 2018 | -13.06% |
| Dec 31, 2017 | -29.53% |